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Abstract Fabry disease is a rare, X-linked inborn error of
glycosphingolipid catabolism caused by a deficiency in the
activity of the lysosomal enzyme, α-galactosidase A. In
affected patients, the enzyme substrate, globotriaosylcer-
amide (Gb3), accumulates in cells of various tissues and
organs. Lysosomal accumulation of Gb3 begins in utero,
and signs and symptoms of Fabry disease emerge in
childhood and adolescence. The earliest presenting symp-
toms are typically neuropathic pain and gastrointestinal
problems, which can have a substantial impact on health-
related quality of life. Life-threatening major organ
involvement is rare in young patients, but signs of kidney
dysfunction (e.g., proteinuria), left ventricular hypertrophy,
and stroke have been reported in children. There are two
enzyme preparations for therapy: agalsidase alfa and beta.
In two clinical trials of enzyme replacement therapy (ERT)
with agalsidase alfa, including 37 children, boys demon-
strated reductions in plasma Gb3 levels, and both boys and
girls reported reductions in neuropathic pain and in the use
of neuropathic pain medications. Heart rate variability,
which is reduced in boys with Fabry disease, was
statistically significantly improved with 6 months of
agalsidase alfa treatment. In a single clinical study of
agalsidase beta in children (n=16), skin Gb3 deposits and
plasma Gb3 levels were reduced in boys. Differences exist
in the administration and the safety profile of these two
enzyme formulations. Follow-up of these cohorts and
additional studies will be necessary to fully evaluate long-
term efficacy of ERT in children with Fabry disease.
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Introduction
Fabry disease is a rare, X-linked inborn error of glyco-
sphingolipid catabolism caused by a deficiency in the
lysosomal enzyme, α-galactosidase A (α-Gal A) [6]. This
genetic disease (Online Mendelian Inheritance in Man
[OMIM] 301500) occurs in people of all ethnicities, with
an estimated incidence of about 1:117,000 births [47]
although a recent newborn screening study suggests that
the incidence may be as high as 1:3,100 male newborns
[67]. In affected patients, the enzyme substrate globotriao-
sylceramide (Gb3), as well as digalactosyl ceramide, and
blood groups B, B1, and P1 glycolipids accumulate in cells
of various tissues and organs [6, 16, 65]. The storage of
Gb3 within cells contributes to the pathologies associated
with Fabry disease, but the exact mechanism(s) of this
interaction is not yet known.
Fabry disease affects almost all organs. The most serious
complications involve the kidneys, heart, and central
nervous system [43, 44]. The typical presenting symptoms
emerge in childhood and adolescence and are primarily
neurologic in origin [26, 43, 44, 52, 55, 58, 59]. These
neurologic symptoms include acroparesthesia or neuropathic
pain that may be triggered by changes in temperature [23,
42], altered heat and cold sensitivity [23, 50], hearing loss
[18, 50, 51], and dyshidrosis [37]. Gastrointestinal (GI)
involvement, characterized by abdominal pain, diarrhea,
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University Children’s Hospital, Mainz, Germanyconstipation, nausea, and vomiting, also may be of neurologic
origin [25]. Most patients have angiokeratomas (Fig. 1)[ 33],
and many experience whorled-shaped corneal opacities
(cornea verticillata) that do not usually affect vision
(Fig. 2)[ 66]. Pain and GI symptoms are responsible for a
reduced quality of life in Fabry disease patients [20, 48].
The life-threatening complications of Fabry disease occur
almost exclusively during adulthood. These complications
include kidney dysfunction progressing to end-stage renal
disease (ESRD) [7], cardiomyopathy and valvular dysfunc-
tion [30, 31, 39], and a high incidence of stroke [49, 61].
The pathologic changes responsible for these events may be
irreversible in adults (e.g., the presence of myocardial
fibrosis [74]). Major organ involvement is the primary
cause of premature mortality in Fabry disease [43, 44].
In contrast to many X-linked diseases, female hetero-
zygotes cannot be considered merely carriers of the
mutation. Indeed, all of the signs and symptoms found in
males with Fabry disease also have been reported in
females [13, 43, 73, 75]. The age of onset of individual
manifestations and the severity of symptoms are much
more varied in females than in males. For example, cardiac
involvement is common in heterozygotes [29], but occurs
about 10 years later than in hemizygous men with Fabry
disease [30]. In kidney dysfunction, the progression to
ESRD is less common in female Fabry patients than in
males [43]. Skewed X-chromosome inactivation [41]i s
thought to be responsible for the presentation of signs and
symptoms of Fabry disease in female patients [45], but
recent studies have concluded that skewed X-chromosome
inactivation is insufficient to explain the variable pene-
trance of X-linked diseases in general [11] and does not
explain the severity of Fabry disease in women [45].
Pediatric Fabry disease
Natural history
Lysosomal accumulation of Gb3 begins in utero, and
cellular inclusions of Gb3 have been detected in fetal
kidney and podocytes [10, 12, 70], cardiomyocytes, and the
cornea. Gb3 inclusions also have been found in the
maternal portion of the placenta from a heterozygous
mother carrying a nonaffected child [53] and in both
maternal and fetal placental tissue of a heterozygous mother
carrying an affected son [72]. Interestingly, placental tissue
from a nonaffected mother carrying a heterozygous female
was free of Gb3 storage material [72]. Despite this evidence
of accumulation of Gb3 at birth, the natural course of the
disease is very heterogeneous and signs and symptoms may
take years to emerge.
Four published studies summarize the expression of
Fabry disease in children and adolescents. Ries and
colleagues described the clinical phenotype in 35 male
and female patients 1 to 21 years of age at four European
sites [59]. In a separate study, Ries and coworkers studied
25 boys between 6 and 18 years of age at the National
Institutes of Health (NIH, USA) [58]. Ramaswami et al.
described 40 boys and 42 girls between 7 and 18 years of
age who were enrolled in the Fabry Outcome Survey (FOS)
[55]. Most recently, Hopkin and colleagues issued the
initial report describing the characteristics of Fabry disease
in 352 children and adolescents enrolled in the Fabry
Registry [26], another international patient registry. Table 1
provides a summary of the primary findings of these
studies. With few exceptions, common signs and symptoms
of Fabry disease were more prevalent in boys than in girls.
For example, acroparesthesia or neuropathic pain was
reported in 63% of boys and in 46% of girls. Similarly,
Fig. 1 This image shows typical angiokeratomas in the right arm of a
15-year-old boy with Fabry disease. These lesions appeared from the
age of 8 years and extended to all the right side of the body, together
with recurrent acroparaesthesias, abdominal pain, diarrhea, cefalea,
and increased fatigability with exercise intolerance. He started ERT at
our institution (GP-M, Germans Trias Hospital, Badalona) with
agalsidase alfa, 5 years ago, with excellent tolerance and is now
(20 years of age) working regularly with much improvement in pain
and physical activity. Proteinuria, decreased GFR, or LVH has not
been detected to date
Fig. 2 Typical image of corneal opacities with a whorl pattern, known
as cornea verticillata. This uncommon finding is very useful for
diagnosis, but runs totally asymptomatic (slit lamp examination
photograph kindly provided by Susanne Pitz, Mainz, Germany)
1356 Eur J Pediatr (2009) 168:1355–1363GI problems were reported in 33% of the boys and in 19% of
the girls. Interestingly, kidney dysfunction (primarily pro-
teinuria) appeared to be more common in girls than in boys.
The onset of symptoms is typically earlier in boys than
in girls. In the Fabry Registry, the onset of symptoms in
boys occurred at a median age of 6 years, compared with
9 years in girls [26]. GI symptoms, including abdominal
pain and diarrhea, were reported at an earlier age in boys
(median age=5 years) than in girls (median age=9.5 years)
[26]. An earlier onset for neuropathic pain in boys was
reported in FOS (median 7.6 years in boys, 15.6 years in
girls) [55]. The early expression of the Fabry phenotype is
further illustrated by the fact that in these studies only one
boy and four girls were reported as being free of any signs
and symptoms related to Fabry disease. The contribution of
children, including both boys and girls, to the total number
of Fabry patients included in the registries is around 20%.
However, because some asymptomatic girls and boys might
not be included in the database of some centers, these
registries may be biased to more severely affected children
and thus not necessarily reflect the actual natural history of
the disease.
The signs and symptoms of Fabry disease (Table 1) can
have a significant impact on quality of life. Ries and
colleagues [58] used the Child Health Questionnaire [34,
35] and reported that bodily pain-related quality-of-life
scores were significantly reduced, compared with boys in
the general population. Other dimensions of quality of life
were similarly reduced in Fabry boys although the
reduction was significant only for parent-assessed mental
health in boys under 10 years of age. Hopkin and
coworkers used the SF-36 quality-of-life questionnaire in
14 male and 26 female patients ≥14 to <18 years of age and
reported that the male patients exhibited significantly
reduced quality of life in seven of the eight SF-36 subscales
(except for Role Emotional) and that the female patients
reported significantly reduced Body Pain and General
Health subscales, compared with the general US population
aged 18 to 25 years [26].
An important observation from these studies is that some
signs of major organ involvement already were present at
an early age. For example, substantial loss of glomerular
filtration rate (GFR) was found in two boys, one 9-year-old
with a creatinine clearance (Ccr) of 62 mL/min/1.73 m
2
[59] and the other a 4-year-old with an estimated GFR of
56 mL/min/1.73 m
2 [26]. Similarly, proteinuria, one of the
initial signs of kidney dysfunction, was detected in 27 of
the children in these studies, with a higher prevalence in
girls compared with boys. Cardiac involvement, including
left ventricular hypertrophy (LVH) and valvular changes,
also was present. In the NIH study, 28% of the boys had a
left ventricular mass (LVM) indexed to height (g/m
2.7) that
was greater than the 95th percentile for boys without Fabry
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Eur J Pediatr (2009) 168:1355–1363 1357disease, and LVH was diagnosed in a 6-year-old boy [58]
and in a 13-year-old girl [55]. Other studies also have
documented the early onset of major organ involvement in
Fabry disease. LVH has been reported in boys and girls
under 18 years of age [32]. Stroke has been reported in
14- and 16-year-old boys [21, 57], and cerebrovascular
abnormalities have been found in boys as young as 8 years
old [8]. Histologic evidence of Fabry-related renal abnor-
malities was described by Gubler et al. in a 12-year-old boy
and an 8-year-old girl [22], and recently, renal biopsy
findings in seven children with minimal albuminuria have
been reported by Tondel and coworkers [68]. Typical lipid
deposits in different renal cells are observed by electron
microscopy (Fig. 3). Reduction in heart rate variability has
been reported in boys in two separate studies [32, 57].
Although this change is likely neurologic in origin, it is a
risk factor for cardiac sudden death in adults [69].
Diagnosis
Diagnosis is readily performed by determining α-Gal A
activity in leukocytes, Gb3 concentrations in plasma and
urine, and by determination of α-Gal A gene mutations.
Gb3 deposits may be demonstrated with histology of skin
and kidney in patients with angiokeratomas or renal
pathology manifestations such as proteinuria and/or de-
creased GFR, respectively.
Because the presenting signs and symptoms of Fabry
disease are nonspecific (e.g., acroparesthesias, nonspecific
GI symptoms), the diagnosis may be delayed, especially in
the absence of a family history of Fabry disease. In the
FOS, the delay between onset of symptoms and diagnosis
was 12 years in both genders [3]. In the Fabry Registry, the
median age at diagnosis was 9 years, and 18% of boys and
12.6% of girls were diagnosed before the onset of
symptoms [26]. A pedigree analysis can be useful in
identifying at-risk individuals [36] or in diagnosing Fabry
disease [5, 36].
Enzyme replacement therapy
α-Gal A has been developed for enzyme replacement
therapy (ERT) for Fabry disease. Two forms of the enzyme
are available: agalsidase alfa and agalsidase beta. Agalsi-
dase alfa (Replagal
®, Shire Human Genetic Therapies, Inc.,
Cambridge, MA, USA) is produced in a continuous human
cell line [63] by gene activation and is used at a dose
of 0.2 mg/kg infused intravenously every other week
(EOW). Agalsidase alfa is typically infused over a 40-min
period without routine premedication. Agalsidase beta
(Fabrazyme
®, Genzyme Corporation, Cambridge, MA,
USA) is produced in Chinese hamster ovary cells and is
administered at a dose of 1.0 mg/kg intravenously EOW
[15]. Patients are usually premedicated with an antipyretic
before infusion, which initially may take >4 h [17]. The two
forms share the same amino acid sequence, but they have
distinct glycosylation patterns, most likely because of the
different manufacturing methods [38].
Clinical trials in adults of both forms of the enzyme have
resulted in biochemical and clinical evidence of efficacy.
Agalsidase alfa reduced plasma Gb3 levels and urinary
excretion of Gb3 and stabilized kidney function in adult males
[62, 64]. Agalsidase alfa also was reported to reduce the
severity of neuropathic pain [62], improve GI symptoms [25],
reduce LVM in adult males with LVH [27], and improve
quality-of-life measures [24]. Agalsidase beta has demon-
strated similar biochemical responses [15], and it also appears
to stabilize kidney function [19]. In a phase IV study,
agalsidase beta tended to reduce the incidence of major
adverse events (i.e., progression of kidney dysfunction,
myocardial infarction, stroke, death) in patients with ad-
vanced disease at baseline, but this beneficial effect was only
statistically significant in a post hoc, per protocol analysis [2].
Both agalsidase alfa and agalsidase beta are approved in
over 40 countries worldwide, including the countries of the
European Union. ERT for Fabry disease is expensive,
currently costing about €150,000 per year for treatment of
adults. Because of its cost, the availability of ERT may
depend on the health-care system within each country.
Fig. 3 Lipid deposits are characterized by electron microscopy and
may be seen in different renal cell types: podocytes, endothelial
glomerular cells, and tubular cells, primarily distal. These deposits
may be cleared with ERT; however, clinical evolution depends mainly
on the presence of associated renal lesions, such as tubulo-interstitial
fibrosis and/or glomerulosclerosis. This photo shows abundant lipid
deposits in podocytes of a 17-year-old female Fabry patient with
proteinuria of 500 mg/24 h (kindly provided by Roser Torra, Fundació
Puigvert, Barcelona)
1358 Eur J Pediatr (2009) 168:1355–1363Clinical trials of agalsidase alfa in children
Three studies of ERT in pediatric Fabry disease patients
have been published with agalsidase alfa [54, 56, 57]. In
each of these studies, agalsidase alfa was administered at a
dose of 0.2 mg/kg infused intravenously EOW. The
pharmacokinetics of agalsidase alfa in pediatric patients
are similar to those in adults, with the exception that
serum clearance tended to be slightly faster in children
(Fig. 4)[ 56]. Some children exhibited a reduction in
serum clearance after 6 months of therapy. This phenom-
enon also was seen in some adults; the mechanism
responsible for this change is not known. The area under
the time–serum concentration curve was not associated
with the percentage reduction in plasma levels of Gb3 in
either children or adults. An important conclusion from
this study was that dose did not need to be adjusted to
account for the slightly faster serum clearance seen in
children compared with adults. This conclusion is based
on the fact that after intravenous (i.v.) infusion, agalsidase
alfa is removed from the blood by mannose-6-phosphate-
mediated cellular internalization and transits into the
lysosomes. Once within the lysosomes, the enzyme is
activated by the low pH and is presumed to remain in the
lysosome until eventually degraded. Thus, because of this
one-way transit, serum clearance is not a measure of
whole body clearance, as is true with most conventional
pharmaceuticals, but is only a measure of the efficiency of
transport of the enzyme to its ultimate site of action, the
lysosome.
Ries and colleagues conducted a 6-month, open-label
study of agalsidase alfa (0.2 mg/kg, i.v. EOW without
routine premedication) in children and adolescents that
was designed to assess the safety and efficacy of ERT
in this patient population [57]. Nineteen boys and five
girls, 6 to 18 years of age, were enrolled in the study.
Fabry disease had been confirmed in the boys by
demonstrating a reduction in α-Gal A activity in
peripheral leukocytes and in the girls by mutation
analysis. Agalsidase alfa was generally well tolerated,
and all of the patients completed the study. Infusion
reactions, which usually consist of fever, rigors, nausea,
and flushing, occurred in seven (six boys, one girl) of
24 patients (three patients experienced one, three
patients experienced three, and one patient experienced
five infusion reactions). None of the infusion reactions
was considered to be severe, and in only one case was
an infusion stopped and not restarted because of an
infusion reaction. During subsequent infusions, premed-
ication with an antihistamine and/or corticosteroids was
used by five of these patients. During the study, one
17-year-old boy tested positive for immunoglobulin G
(IgG) anti-agalsidase alfa antibodies, but, by the end of
the study, tolerance had occurred and he reverted
to seronegative. No immunoglobulin E (IgE) anti-
agalsidase alfa antibodies were detected in any of the
children. Mean plasma levels of Gb3 were reduced by
about 50% in boys, providing biochemical evidence of
the efficacy of agalsidase alfa (plasma Gb3 levels were
not elevated in the girls and did not change during
therapy). Of the 11 patients who were taking anticon-
vulsant agents for neuropathic pain at baseline, six were
able to stop or reduce their use (P=0.012). In the entire
study population, decreases in pain, as assessed by the
Brief Pain Inventory (BPI) [9] “pain at its worst” score,
were demonstrated in both boys and girls (P=NS).
Further evidence suggesting a benefit of agalsidase alfa
was seen in seven patients who had an estimated
glomerular filtration rate (eGFR) >135 mL/min/1.73 m
2
at baseline. Hyperfiltration may be one of the initial signs
of kidney dysfunction, and in these patients mean eGFR
returned to the normal range after 9 weeks of treatment.
Sweating was assessed in 13 patients by quantitative
sudomotor axon reflex test. After 25 weeks of agalsi-
dase alfa, mean sweat volume increased from 0.48 to
0.73μL/mm
2, and measurable sweat volumes were
observed in the three patients with anhidrosis at baseline.
Of interest was the finding that boys had reduced heart
rate variability at baseline and that 25 weeks of agalsidase
alfa significantly improved all measures of this cardiac
risk factor (Fig. 5).
A similar open-label study by Ramaswami and
coworkers treated nine boys and four girls with Fabry
disease with agalsidase alfa at 0.2 mg/kg, i.v. EOW for
23 weeks [54]. Eleven infusion reactions occurred in
four boys and were mild or moderate in severity. Two
Fig. 4 The relationship between age and serum clearance of
agalsidase alfa in pediatric Fabry disease patients. Boys, filled
squares; girls, open squares. The line was calculated by linear
regression (clearance=5.58–0.158 × age [years]; P=0.051 for slope).
Adult clearance values are shown for comparison (mean ± standard
deviation). From Ries et al. [56] © 2007 Springer. Reprinted by
permission of SAGE Publications, Inc
Eur J Pediatr (2009) 168:1355–1363 1359of these boys received premedication prior to subsequent
infusions. One boy developed IgG anti-agalsidase alfa anti-
bodies during the study; no patient developed IgE anti-
agalsidase alfa antibodies. All male patients had elevated
plasma Gb3 levels at baseline, and after 23 weeks of
agalsidasealfatreatment,meanplasmaGb3levelwasreduced
byabout50%.Painscorestendedtodecrease;theaverageBPI
“pain at its worst” score declined from 2.8 at baseline to 1.5 at
week 23, and the average BPI “pain on average” score
declined from 2.2 at baseline to 0.9 at week 23. Importantly,
the two patients with the “pain at its worst” scores of 7–10
(severe pain) at baseline experienced improvement during the
study.
Clinical trial of agalsidase beta in children
An open-label study of agalsidase beta in pediatric Fabry
disease patients included 16 children (14 boys, two girls)
between 8 and 16 years of age [77]. The children were
observed for a 12-week baseline period and then treated
with agalsidase beta (1.0 mg/kg) infused i.v., EOW for
48 weeks. These patients were routinely premedicated with
an antipyretic before the 2- to 4.5-h infusion; antihistamines
also were used in some cases. Superficial dermal capillary
endothelial cell deposits of Gb3 were completely cleared at
week 24 and remained so through week 48, as evaluated by
a semiquantitative histologic scoring system. As was true in
the studies described above, plasma Gb3 was reduced in
boys (from a median of 15.9 to 6.3 μg/mL) during the
study. GI symptoms, including postprandial pain and
vomiting, also appeared to decrease in incidence during
the study. Despite premedication, infusion-associated reac-
tions were reported in six boys of 16 patients, and one boy
withdrew from the study because of a severe infusion
reaction (he subsequently tested positive for IgE antibodies
after 3 months on commercial treatment). Overall, IgG anti-
agalsidase beta antibodies were detected in 11 of 16
patients, with most experiencing a reduction in antibody
titer during the remainder of the study.
Commentary
No head-to-head studies of the two forms of α-Gal A used
for ERT in pediatric patients with Fabry disease have been
conducted, and thus comparisons of the safety and efficacy
of agalsidase alfa and agalsidase beta in children based on
the published studies are difficult [54, 56, 57]. Reduction of
plasma Gb3 levels in the male patients was similar for the
two drugs (i.e., about 50%). The magnitude of the reduction
is similar to that reported in clinical trials of the two drugs
in adult male patients [64, 76]. Patients in all three studies
reported subjective improvement of symptoms (primarily
pain) during ERT, but the only objective evidence of benefit
was the statistically significant improvement of abnormal
heart rate variability in boys treated with agalsidase alfa
[57], and the disappearance of Gb3 deposits in the dermal
capillary endothelial cells [77]. Different assay methods
used to detect antibodies in each study may have influenced
the results, but the development of IgG antibodies to each
form of the enzyme appeared to be different, with 69% of
the boys treated with agalsidase beta seroconverting [77],
compared with 5.3% [57] and 11.1% [54] in the studies of
agalsidase alfa. This difference is consistent with the results
reported in adults. It is not clear what the pharmacologic
consequences are concerning the development of IgG
antibodies. In a head-to-head study in adults [71], most of
the men with antibodies presented neutralizing activity, and
those men with antibodies who were treated with agalsidase
alfa (0.2 mg/kg i.v. EOW) exhibited a smaller reduction in
urinary Gb3 than patients treated with agalsidase beta
(1.0 mg/kg i.v. EOW) or in patients without antibodies.
However, with respect to clinical evaluation of renal
function, there was no difference between patients who
developed antibodies and those who did not, regardless of
which form of the enzyme they were receiving [46, 71].
Schiffmann and colleagues previously had reported that
patients treated with agalsidase alfa who developed tran-
sient or persistent IgG antibodies against the enzyme also
had a smaller reduction in urinary Gb3, but that no effect of
Fig. 5 Agalsidase alfa improves all indices of heart rate variability in
boys with Fabry disease (N=18). Heart rate variability was assessed
quantitatively from 2-h ambulatory monitor recordings; measured
were mean beat-to-beat interval ([mean RR] milliseconds); SDNN
standard deviation of normal beat to normal beat intervals over the
length of the analysis; SDNN-I mean of the SD of all the RR intervals
for all 5-min segments of the analysis; SDANN-I SD of the mean of all
RR intervals for all 5-min segments of analysis; r-MSSD square root
of the mean of the sum of squares of differences between adjacent
filtered RR intervals; pNN50 percentage of differences between
adjacent filtered RR intervals that are >50 ms for the entire analysis
(adapted from Ries et al. [57]). *P<0.02, **P<0.01 (Wilcoxon-signed
rank test) compared with baseline. ms milliseconds
1360 Eur J Pediatr (2009) 168:1355–1363antibodies on the progression of kidney dysfunction was
apparent [64]. Importantly, in the pediatric studies, the
development of IgE anti-agalsidase antibodies was reported
only for agalsidase beta. IgE antibodies to agalsidase beta
have been consistently reported in about 6% of adult
patients participating in clinical studies [2, 15]. No IgE
antibodies directed against agalsidase alfa have been
reported in any clinical studies.
Agalsidase alfa has been reported to significantly improve
neuropathicpaininadultmenandwomenwithFabrydisease
[4, 62]. In clinical studies, agalsidase alfa tended to reduce
the severity of neuropathic pain in children [54, 57] and
significantly reduced the need for neuropathic pain medi-
cation [57]. The latter observation is important because the
anticonvulsant drugs used to treat neuropathic pain may
have substantial side effects and are reported to negatively
influence behavior and cognitive function [28, 40].
The issue of when to initiate ERT for Fabry disease
remains to be determined. Studies in adults suggest that
patients in the early stages of organ involvement may respond
better to ERT than patients with advanced disease. For
example, Schiffmann and colleagues reported that agalsidase
alfa preserved kidney function (as measured by eGFR) in
Fabry disease patients with stage 1 or 2 chronic kidney
disease (CKD) at baseline, but was less effective in patients
with the more serious stage 3 or higher CKD [64]. Similarly,
Banikazemi et al. reported that agalsidase beta had a lesser
effect in reducing the incidence of major clinical events in
patients with proteinuria in excess of 1.0 g/day, which they
considered a marker for more advanced disease [2].
The observations in adults suggest that initiation of ERT
in childhood might slow or stop the progression of organ
damage before irreversible changes occur. As noted above,
Gb3 accumulation begins during fetal development [10, 12,
70], but signs and symptoms of Fabry disease take years to
appear. ERT initiated in childhood might delay or prevent
major organ damage by reducing Gb3 storage, but final
evidence supporting or refuting this concept has not been
demonstrated [60].
Interpretation of the small studies presented here is
complicated by the lack of a placebo control group, the
range of ages of the patients studied, their different
mutations, the natural variation in the phenotypic expres-
sion, and the progression of signs and symptoms seen in
Fabry patients. To date, no surrogate markers have been
described that might identify Fabry disease patients who are
at greatest risk for disease progression and who might
benefit most from early ERT. Gb3 is a bad biomarker of
disease activity but, recently, some hope has been deposited
in its derivative (lyso-Gb3) that may better reflect patho-
physiological changes [1].
Current guidelines indicate that ERT should be initiated
in all males >16 years and in pediatric males at the time of
development of significant symptoms [14]. Asymptomatic
boys should be considered for ERT between the ages of 10
and 13 years, but the actual age at which ERT should be
started in boys remains to be decided by the physicians,
family, and patient. These guidelines also state that ERT in
female patients should be started only after the onset of
significant symptoms.
After 7 years of ERT in children with Fabry disease and
in accord with the three clinical trials presented in this
work, safety has been convincingly demonstrated. Howev-
er, more controlled trials must be done in order to
demonstrate the ultimate objective of ERT in children that
is the long-term prevention of adult complications. It is
important to note that, in addition to ERT, adjunct therapies
and preventive measures should be part of the treatment
plan for all patients. For example, angiotensin-receptor
blockers or angiotensin-converting enzyme inhibitors may
be used to prevent or reduce proteinuria, dietary restrictions
and H2 blockers may improve GI problems, and anticon-
vulsants (e.g., phenytoin, carbamazepine) are indicated for
the treatment of neuropathic pain.
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